SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jesspro who wrote (4434)12/7/2016 10:03:27 AM
From: Biomaven  Read Replies (1) | Respond to of 4474
 
Yes, but it won't be the same at all - it will be much better.



To: jesspro who wrote (4434)12/8/2016 10:54:36 PM
From: rkrw  Respond to of 4474
 
Zykadia data in 2nd line ALK for comparison.

The latest findings demonstrated that patients with ALK-positive NSCLC had significantly longer median PFS of 5.4 months with (Zykadia) ceritinib compared with 1.6 months with chemotherapy (HR, 0.49; P <.001). - See more at: onclive.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News